Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders (ROP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether Integrated Treatment is effective in the treatment of anxiety and/or depression with co-occurring substance use disorders.
| Condition | Intervention |
|---|---|
|
Anxiety Disorders Mood Disorders Substance Use Disorders |
Behavioral: Integrated mental health and substance use treatment Behavioral: Treatment as usual |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effects of Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders |
- The Symptom Check List 90 (SCL90-r), The Alcohol Use Disorder Identification Test (AUDIT), The Drug Use Disorder Identification Test (DUDIT). [ Time Frame: Change during 6 and 12 months follow-up ] [ Designated as safety issue: No ]
We use the SCL-90r to measure symptoms in regard to anxiety, depression and the General Severity Index.
We use the AUDIT and the DUDIT to measure changes in the use of alcohol and illegal drugs respectively.
- The Addiction Severity Index (Europ ASI) [ Time Frame: Change during 6 and 12 months follow up ] [ Designated as safety issue: No ]The Addiction Severity Index (Europ ASI) is used to assess changes in the use of alcohol and illegal substances during the course of the trial.
| Enrollment: | 76 |
| Study Start Date: | March 2007 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Integrated treatment
Evidence-based psychosocial and pharmacological treatment of both the substance use disorder and the mental health disorder is provided at the same time and by the same therapists in a comprehensive way.
|
Behavioral: Integrated mental health and substance use treatment
Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
Other Names:
|
|
Active Comparator: Treatment as usual
Non-manualized clinic-based treatment provided by therapists without formal training in integrated treatment of co-occurring disorders.
|
Behavioral: Treatment as usual
Non-standardized psychiatric outpatient treatment
Other Names:
|
Detailed Description:
Patients with mental disorders and co-occuring substance use disorders are characterized by high suicide rates, high treatment drop-out rates and long-lasting interpersonal, work, school, health and legal problems. Because mental disorders and substance use disorders co-exist and interact, it may be important to provide a treatment that addresses the substance misuse and mental health problems in an integrated and comprehensive way. Additionally, the health services for patients with mental health and substance use disorders are usually provided by different services and health professionals that rarely cooperate or have qualifications on both kinds of disorders. This also calls for an integration of the services on an organizational level. This approach of integrating services and treatment approaches for both diseases in a comprehensive way is called Integrated Treatment. Several studies have shown that Integrated Treatment is effective in treating the comorbidity of severe mental illness and substance use disorders. The over-all aim of this study is to evaluate the effects of evidence-based Integrated Treatment in anxiety and/or depression with co-occurring substance use disorders. The effects of the treatment will be assesses on changes in substance use and psychopathology.
Comparison: patients receiving treatment-as-usual or non-manualized treatment at general mental health outpatients clinics.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- clinical diagnosis of substance use disorder
- clinical diagnosis of anxiety disorders
- clinical diagnosis of nonpsychotic mood disorders
- written consent
- planning to live in the catchment area during the treatment
Exclusion Criteria:
- schizophrenia spectrum disorders
- other psychotic disorders
- mental retardation
- nicotine abuse/dependency only
- prescription drug abuse/dependency only
- planning to move out of the catchment area during the study
- not able to read or write Norwegian
Contacts and Locations| Principal Investigator: | Rolf W. Gråwe, Ph.D | Alcohol and Drug Treatment Health Trust in Central Norway; Norwegian Centre of Addiction Research, University of Oslo |
More Information
Additional Information:
No publications provided
| Responsible Party: | Rolf W. Grawe, Ph.d.; Assistent Professor; University of Oslo, University of Oslo |
| ClinicalTrials.gov Identifier: | NCT00447733 History of Changes |
| Other Study ID Numbers: | 78i068, NFR175394/V50 |
| Study First Received: | March 14, 2007 |
| Last Updated: | March 23, 2012 |
| Health Authority: | Norway: Norwegian Social Science Data Services |
Keywords provided by University of Oslo:
|
mental health substance use treatment |
Additional relevant MeSH terms:
|
Anxiety Disorders Mental Disorders Psychotic Disorders |
Substance-Related Disorders Mood Disorders Schizophrenia and Disorders with Psychotic Features |
ClinicalTrials.gov processed this record on May 19, 2013